The founder of RTW Investments believes biopharma’s five-year bear market is finally coming to an end.In a client letter detailing August results, dated September 2 and obtained by Institutional Investor, the biotech hedge fund firm’s founder, Rod Wong, told clients, “We are increasingly optimistic that